Genetic polymorphism G894T and the prognosis of heart failure outpatients;Polimorfismo G894T da óxido nítrico-sintetase endotelial e o prognóstico na insuficiência cardíaca

Arquivos Brasileiros de Cardiologia

Volumn 101, Issue 4, 2013, Pages 352-358

  Tardin, Oziel Marcio Araujo ^a   Pereira, Sabrina Bernardez ^a   Velloso, Monica Wanderley Monçores ^a   Balieiro, Henrique Miller ^b   Costa, Bruno ^a   Alves, Thiago Oliveira ^a   Giro, Camila ^a   Pessoa, Leandro Pontes ^a   Ribeiro, Georgina Severo ^a   Mesquita, Evandro Tinoco ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b Escola de Medicina de Valença   (Brazil)

Author keywords

Ethnicity and health; Genetic; Heart failure; Nitric oxide; Polymorphism

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COHORT ANALYSIS; ELECTROCARDIOGRAPHY; ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; BRAZIL; EPIDEMIOLOGIC METHODS; FEMALE; GENE FREQUENCY; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OUTPATIENTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84887514855     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20130167     Document Type: Article

References (30)

1. Norton RM. Clinical pharmacogenomics: aplications in pharmaceutical R&D. Drugs Discov Today. 2001;6(4):180-185.
2. Silva PS, Lacchini R, Gomes Vde A, Tanus-Santos JE. Pharmacogenetic implications of the eNOS polymorphisms for cardiovascular action drugs. Arq Bras Cardiol. 2011;96(2):e27-34.
3. Gurwitz D, McLeod HL. Genome-wide association studies: powerful tools for improving drug safety and efficacy. Pharmacogenomics. 2009;10(2):157-159.
4. Mariotti S, Capparuccia C, Ripa C, Olivieri F, Lisa R, Procópio A, et al. The role of molecular biology in the diagnosis and treatment of cardiovascular diseases. G Ital Cardiol (Rome). 2010;11(10):730-745.
5. Dayer P, Mérier G, Perrenoud JJ, Marmy A, Leemann T. Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S20-24.
6. Dragovic T, Ajdinovic B, Ilic V, Magić Z, Andelković Z, Kocev N. Individual renal hemodynamic response to chronic angiotensin II receptor blockade and the influence on the renin-angiotensin system gene polymorphisms. Med Pregl. 2010;63(9-10):630-637.
7. Wilkinson E. From mechanics to genetics in cardiology. Eur Heart J. 2009;30(19):2291-2293.
8. Mungrue IN, Husain M, Stewart DJ. The role of NOS in heart failure: lessons from murine genetic models. Heart Fail Rev. 2002;7(4):407-422.
9. Viaro F, Nobre F, Evora PR. Expression of nitric oxide synthases in the pathophysiology of cardiovascular diseases. Arq Bras Cardiol. 2000;74(4):380-393.
10. Katz SD, Khan T, Zeballos GA, Mathew L, Potharlanka P, Knecht M, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation. 1999;99(16):2113-2117.
11. Dias RG, Negrão CE, Krieger MH. Nitric oxide and the cardiovascular system: cell activation, vascular reactivity and genetic variant. Arq Bras Cardiol. 2011;96(1):68-75.
12. Kao WH, Arking DE, Post W, Rea TD, Sotoodehnia N, Prineas RJ, et al. Genetic variations in nitric oxide Synthase 1 adaptor protein are associated with sudden death in US white community-based populations. Circulation. 2009;119(7):940-951.
13. Marsden PA, Heng HH, Scherer S W, Stewart RJ, Hall A V, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993;268(23):17478-17488.
14. Dafni C, Drakoulis N, Landt O, Panidis D, Reczko M, Cokkinos D V. Association of eNOS E298D polymorphism and the risk of myocardial infarction in the Greek population. BMC Med Genet. 2010;11:133.
15. Binkley P F, Nunziatta E, Liu-Stratton Y, Cooke G. A polymorphism of endo thelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. Am Heart J. 2005;149(2):342-348.
16. Hingorami AD, Jia H, Stevens P, Monteith P, Brown M, A common variant in exon 7 of endothelial constitutive nitric oxide synthase gene: identification by single strand conformation polymorphism analysis. Clin Sci. 1995;88(suppl):21.
17. MacNamara DM, Holubkov R, Postava L, Ramani R, Janosko K, Mathier M, et al. Effect of the Asp 298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure, Circulation. 2003;107(12):1598-1602.
18. Taylor AL, The African-American Heart Failure Trial: a clinical trial update. Am J Cardiol. 2005;96(7B):44-48.
19. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, et al. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail. 2009;15(3):191-198.
20. Velloso MW, Pereira S P, Gouveia L, Chermont S, Tardin OM, Gonçalves R, et al. Endohelial nitric oxide synthase Glu298Asp gene polymorphism in a multi-ethnical population with heart failure and controls. Nitric Oxide. 2010;22(3):220-225.
21. Barretto AC, Drumond Neto C, Mady C, Albuquerque DC, Brindeiro Filho D, Braile DM, et al. Sociedade Brasileira de Cardiologia. II Diretrizes da Sociedade Brasileira de Cardiologia para o diagnóstico e tratamento da insuficiência cardíaca. Arq Bras Cardiol. 2002;79(suppl.4):1-30.
22. Serrano NC, Díaz LA, Casas J P, Hingorani AD, Moreno de Lucca D, Páez MC. Frequency of eNOS polymorphisms in the Colombian general population. BMC Genet. 2010;11:54.
23. Tavares LR, Victer H, Linhares JM, de Barros CM, Oliveira MV, Pacheco LC, et al. Epidemiologia da Insuficiência Cardíaca Descompensada em Niterói - Projeto EPICA - Niterói. Arq Bras Cardiol. 2004;82(2):125-128, 121-124.
24. Gaui EN, Klein CH, Oliveira GM. Mortality due to heart failure as a basic or contributory cause of death in three Brazilian states between 1999 and 2004. Rev SOCERJ. 2008;21(3):129-137.
25. Schmidt MI, Duncan BB, Azevedo e Silva G, Menezes AM, Monteiro CA, Barreto SM, et al. Chronic non-communicable diseases in Brazil: burden and current challenges. Lancet. 2011;377(9781):1949-1961.
26. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugiyama K, Ogawa H, et al. Association of missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol. 1998;31(7):1506-1510.
27. Hingorani AD, Liang C F, Fatibene J, Lyon A, Monteith S, Parsons A, et al. A common variant of the endothelial nitric oxide synthase (Glu 298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation. 1999;100(14):1515-1520.
28. Smith NL, Felix J F, Morrison AC, Demissie S, Glazer NL, Loehr LR, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3(3):256-266.
29. Villard E, Perret C, Gary F, Proust C, Dilanian G, Hengstenberget C, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. 2011;32(9):1065-1076.
30. International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-796.